JP2023509212A5 - - Google Patents
Info
- Publication number
- JP2023509212A5 JP2023509212A5 JP2022542256A JP2022542256A JP2023509212A5 JP 2023509212 A5 JP2023509212 A5 JP 2023509212A5 JP 2022542256 A JP2022542256 A JP 2022542256A JP 2022542256 A JP2022542256 A JP 2022542256A JP 2023509212 A5 JP2023509212 A5 JP 2023509212A5
- Authority
- JP
- Japan
- Prior art keywords
- chain
- sequence
- seq
- obscurin
- titin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010020878.7 | 2020-01-09 | ||
| CN202010020878 | 2020-01-09 | ||
| PCT/CN2021/070832 WO2021139758A1 (zh) | 2020-01-09 | 2021-01-08 | 新型多肽复合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023509212A JP2023509212A (ja) | 2023-03-07 |
| JP2023509212A5 true JP2023509212A5 (https=) | 2024-01-16 |
| JP7773981B2 JP7773981B2 (ja) | 2025-11-20 |
Family
ID=76787741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542256A Active JP7773981B2 (ja) | 2020-01-09 | 2021-01-08 | 新型ポリペプチド複合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230120270A1 (https=) |
| EP (1) | EP4089111A4 (https=) |
| JP (1) | JP7773981B2 (https=) |
| KR (1) | KR20220123072A (https=) |
| CN (1) | CN114746440B (https=) |
| AU (1) | AU2021205561A1 (https=) |
| CA (1) | CA3164979A1 (https=) |
| TW (1) | TWI878430B (https=) |
| WO (1) | WO2021139758A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7628966B2 (ja) | 2019-06-04 | 2025-02-12 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | 胸線間質性リンパ球増殖因子に結合可能な抗体およびその使用 |
| CN116601295A (zh) * | 2020-12-03 | 2023-08-15 | 江苏恒瑞医药股份有限公司 | 一种抗tslp抗体药物组合物及其用途 |
| EP4372001A4 (en) * | 2021-07-14 | 2025-02-12 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | ANTIGEN-BINDING MOLECULE SPECIFICALLY BINDING TO HGFR AND EGFR, AND PHARMACEUTICAL USE THEREOF |
| KR20240139065A (ko) | 2022-02-07 | 2024-09-20 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Psma 및 cd3에 특이적으로 결합하는 항원 결합 분자 및 이들의 의약적 용도 |
| MX2024011128A (es) | 2022-03-14 | 2024-09-18 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Molecula de union a antigeno que se une especificamente a gprc5d y cd3 y su uso medico. |
| CN119013295A (zh) * | 2022-04-11 | 2024-11-22 | 江苏恒瑞医药股份有限公司 | 特异性结合egfr和cd28的抗原结合分子及其医药用途 |
| TW202405015A (zh) * | 2022-04-11 | 2024-02-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合ｐｓｍａ和ｃｄ２８的抗原結合分子及其醫藥用途 |
| CN119256017A (zh) * | 2022-06-23 | 2025-01-03 | 江苏恒瑞医药股份有限公司 | 特异性结合dll3和cd3的抗原结合分子及其医药用途 |
| TW202413437A (zh) | 2022-08-05 | 2024-04-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合ｇｕｃｙ２ｃ和ｃｄ３的抗原結合分子及其醫藥用途 |
| CN118221829A (zh) * | 2022-12-21 | 2024-06-21 | 广东菲鹏制药股份有限公司 | 一种il-10单体融合蛋白 |
| TW202511295A (zh) | 2023-08-31 | 2025-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｃｔｌａ４／ｔｉｇｉｔ結合蛋白及其醫藥用途 |
| WO2025082377A1 (zh) * | 2023-10-17 | 2025-04-24 | 江苏恒瑞医药股份有限公司 | 一种抗tslp抗体的药物组合物及其用途 |
| WO2025106278A1 (en) | 2023-11-17 | 2025-05-22 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5889151A (en) | 1989-10-20 | 1999-03-30 | Societe Leb-Tech | Purified human alpha interferon receptor |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP1957541A2 (en) * | 2005-11-21 | 2008-08-20 | Laboratoires Serono SA | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
| EP1963527A2 (en) * | 2005-12-15 | 2008-09-03 | Becton, Dickinson and Company, Wagner, Jaconda | Diagnosis of sepsis |
| EP2162459B1 (en) * | 2007-05-01 | 2017-10-04 | University of Miami | Transcriptomic biomarkers for individual risk assessment in new onset heart failure |
| US9476097B2 (en) * | 2011-04-11 | 2016-10-25 | The Brigham And Women's Hospital, Inc. | Structural mutations in titin cause dilated cardiomyopathy |
| US20150183877A1 (en) * | 2012-07-18 | 2015-07-02 | Eli Lilly And Company | Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains |
| RU2646159C2 (ru) * | 2012-09-14 | 2018-03-01 | Ф. Хоффманн-Ля Рош Аг | Способ получения и отбора молекул, включающих по меньшей мере две различные группировки, и их применение |
| ES2936810T3 (es) * | 2014-05-16 | 2023-03-22 | Pfizer | Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería |
| WO2017106462A1 (en) * | 2015-12-18 | 2017-06-22 | Biogen Ma Inc. | Bispecific antibody platform |
| AU2018334886B2 (en) | 2017-09-22 | 2025-06-26 | WuXi Biologics Ireland Limited | Novel bispecific polypeptide complexes |
| CN109970860A (zh) * | 2017-12-27 | 2019-07-05 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
-
2021
- 2021-01-08 WO PCT/CN2021/070832 patent/WO2021139758A1/zh not_active Ceased
- 2021-01-08 AU AU2021205561A patent/AU2021205561A1/en active Pending
- 2021-01-08 US US17/791,579 patent/US20230120270A1/en active Pending
- 2021-01-08 CN CN202180006946.7A patent/CN114746440B/zh active Active
- 2021-01-08 EP EP21738017.9A patent/EP4089111A4/en active Pending
- 2021-01-08 JP JP2022542256A patent/JP7773981B2/ja active Active
- 2021-01-08 KR KR1020227026346A patent/KR20220123072A/ko active Pending
- 2021-01-08 CA CA3164979A patent/CA3164979A1/en active Pending
- 2021-01-08 TW TW110100845A patent/TWI878430B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023509212A5 (https=) | ||
| AU2022218544B2 (en) | Hetero-dimeric multi-specific antibody format | |
| JP7138046B2 (ja) | 二特異性抗体基幹 | |
| RU2558301C2 (ru) | Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие | |
| TWI585104B (zh) | 基於vl和vhh可變區衍生物的高親和力抗聚集抗體 | |
| JP2018526981A5 (https=) | ||
| WO2013064701A2 (en) | Bispecific antibodies and methods for isolating same | |
| JP2009517006A5 (https=) | ||
| EP4303231A1 (en) | Bispecific antibody | |
| JP2024507540A5 (https=) | ||
| JP2022504826A5 (https=) | ||
| JP2024507693A5 (https=) | ||
| JP2023511376A5 (https=) | ||
| WO2022057875A1 (zh) | 靶向4-1bb的单域抗体、其融合蛋白、药物组合物及用途 | |
| JP2024504162A5 (https=) | ||
| US20250197481A1 (en) | Antigen Binding Polypeptides, Antigen Binding Polypeptide Complexes and Methods of Use Thereof in HIV | |
| JP7805362B2 (ja) | Ｃｄ３に結合するポリペプチド構築物 | |
| CN119894936A (zh) | 抗her2抗体及其用途 | |
| JP2025513855A5 (https=) | ||
| JP2024537397A5 (https=) | ||
| EA051713B1 (ru) | Биспецифическое антитело | |
| TW202222824A (zh) | Egfr結合複合物及其製備和使用方法 | |
| NZ807450A (en) | Antibodies binding to gprc5d | |
| RU2022133024A (ru) | Анти-cd3 антитело и молекула, содержащая это антитело |